The Importance of Antiviral Prophylaxis against Hepatitis B Virus in Patients under Immunosuppressive Therapy

AKSOY F., KAYA S., Karakoc H. N., YILMAZ G., Atalar S., Koksal I.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, vol.25, no.2, pp.50-54, 2019 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.4274/vhd.galenos.2019.2018.0027
  • Journal Name: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.50-54
  • Keywords: Hepatitis B virus, prophylaxis, immunosuppressive therapy, REACTIVATION, MANAGEMENT, INFECTION, GUIDELINES
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

Objectives: Immunosuppressive (IS) therapies present a risk of reactivation in patients with previous or known hepatitis B virus (HBV) infection and may cause mortality and morbidity. Before starting these therapies, patients should be tested for HBV serology and evaluated for antiviral therapy.